Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Patient
 Drug Development
 Resources
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Jobs
 

EquipNet Auction: Looking to sell your pre-owned equipment? Sell it Now! Don't Wait!

Our Newest Cartoon Illustrates: "Women's History Month"


Addresses to Send Applications

  • Full drug marketing application submissions under 21 CFR subpart 314.50 and 314.54 should be directed to:
  • Center for Drug Evaluation and Research
    Food and Drug Administration
    Document and Records Section
    5901-B Ammendale Rd
    Beltsville, Md. 20705-1266

  • Abbreviated new drug applications under 21 CFR subpart 314.94, and amendments, supplements, and resubmissions; and
  • Abbreviated antibiotic drug application submissions, as well as items sent by parcel post or overnight courier service to the Office of Generic Drugs, should be directed to:
  • Office of Generic Drugs (HFD-600)
    Center for Drug Evaluation and Research
    Food and Drug Administration
    Metro Park North II, Room 150
    7500 Standish Place
    Rockville, MD 20855

  • Correspondence not associated with a particular application should be addressed specifically to the intended office or division and to the person as follows:
  • Center for Drug Evaluation and Research
    Food and Drug Administration
    Attn: [insert name of person]
    HFD-[insert mail code of office or division]
    5600 Fishers Lane
    Rockville, MD 20857

    Source: U.S. Food and Drug Administration Center for Drug Evaluation and Research Handbook.


    Back to The New Drug Development Process

     
    Email thie page to a friend. Email This Page
    to a Friend
    Print this page. Print This
    Page
    © 1997 - 2023 Info.Resource, Inc. All rights reserved.
    Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

    WashingtonLifeScience.com is owned and published by Info.Resource, Inc.